Vladimir Vexler Net Worth

The estimated Net Worth of Vladimir Vexler is at least $4.91 million dollars as of 9 March 2021. Vladimir Vexler owns over 114,240 units of Coherus Biosciences Inc stock worth over $71,003 and over the last 6 years he sold CHRS stock worth over $3,077,640. In addition, he makes $1,757,230 as Chief Scientific Officer at Coherus Biosciences Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Vladimir Vexler CHRS stock SEC Form 4 insiders trading

Vladimir has made over 2 trades of the Coherus Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 114,240 units of CHRS stock worth $1,856,400 on 9 March 2021.

The largest trade he's ever made was selling 114,240 units of Coherus Biosciences Inc stock on 9 March 2021 worth over $1,856,400. On average, Vladimir trades about 11,336 units every 6 days since 2018. As of 9 March 2021 he still owns at least 53,386 units of Coherus Biosciences Inc stock.

You can see the complete history of Vladimir Vexler stock trades at the bottom of the page.

Vladimir Vexler biography

Dr. Vladimir Vexler Ph.D is Chief Scientific Officer of the company. Dr. Vexler serves as our Chief Scientific Officer and served as Executive Vice President of Analytical and Translational Sciences since April 2017. Dr. Vexler served as our Senior Vice President of Translational & Development Sciences since June 2016, and our Vice President, Preclinical Development since January 2013. Prior to that, Dr. Vexler was a Senior Research Leader, Biotherapeutics at Hoffman-La Roche, where he acted as Global scientific leader for nonclinical safety of biotherapeutics and chaired Roche pRED Global Biotherapeutics Safety Team since December 2009. Dr. Vexler began his career as a post-doctoral fellow at the Department of Radiology at UCSF. Dr. Vexler received his M.A. in Chemistry from Lomonosov Moscow State University and his Ph.D. from the Institute of Chemical Physics, Academy of Science, Moscow.

What is the salary of Vladimir Vexler?

As the Chief Scientific Officer of Coherus Biosciences Inc, the total compensation of Vladimir Vexler at Coherus Biosciences Inc is $1,757,230. There are 4 executives at Coherus Biosciences Inc getting paid more, with Dennis Lanfear having the highest compensation of $5,361,710.

How old is Vladimir Vexler?

Vladimir Vexler is 62, he's been the Chief Scientific Officer of Coherus Biosciences Inc since 2018. There are 8 older and 7 younger executives at Coherus Biosciences Inc. The oldest executive at Coherus Biosciences Inc is Dr. Barbara K. Finck M.D., 74, who is the Acting Chief Medical Officer.

What's Vladimir Vexler's mailing address?

Vladimir's mailing address filed with the SEC is COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY, CA, 94065.

Insiders trading at Coherus Biosciences Inc

Over the last 10 years, insiders at Coherus Biosciences Inc have traded over $94,360,509 worth of Coherus Biosciences Inc stock and bought 594,589 units worth $8,026,656 . The most active insiders traders include Llc Fmr, August J. Troendle et James Healy. On average, Coherus Biosciences Inc executives and independent directors trade stock every 26 days with the average trade being worth of $64,928. The most recent stock trade was executed by Mats Wahlstrom on 1 February 2024, trading 59,988 units of CHRS stock currently worth $100,180.

What does Coherus Biosciences Inc do?

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp

Complete history of Vladimir Vexler stock trades at Coherus Biosciences Inc

Coherus Biosciences Inc executives and stock owners

Coherus Biosciences Inc executives and other stock owners filed with the SEC include:

• Dennis Lanfear,
  Chairman of the Board, President, Chief Executive Officer
• Jean-Frederic Viret,
  Chief Financial Officer
• Dennis M. Lanfear,
  Chairman, Pres & CEO
• Vincent Anicetti,
  Chief Operating Officer
• Vladimir Vexler,
  Chief Scientific Officer
• Vladimir Vexler,
  Chief Scientific Officer
• Mats Wahlstrom,
  Lead Independent Director
• V. Bryan Lawlis,
  Independent Director
• Mary Szela,
  Independent Director
• Ali Satvat,
  Independent Director
• James Healy,
  Independent Director
• Samuel Nussbaum,
  Independent Director
• Kimberly Tzoumakas,
  Director
• Thomas Fitzpatrick,
  Chief Legal Officer
• Dr. Barbara K. Finck M.D.,
  Acting Chief Medical Officer
• Richard L. Hameister,
  Chief Quality Officer
• Michael Chen,
  Sr. VP of Commercial Analytics & Trade
• Michael A. Fleming,
  Chief Strategy Officer
• Rebecca Sunshine,
  Exec. VP of HR
• Chris Thompson,
  Exec. VP of Sales
• McDavid Stilwell,
  Chief Financial Officer
• Alan C. Herman,
  Chief Scientific Officer
• August J. Troendle,
  Director
• Christos Richards,
  Director
• Peter K. Watler,
  Chief Technical Officer
• Barbara K Finck,
  Chief Medical Officer
• Rita A Karachun,
  
• Llc Fmr,
  10% owner
• Biosimilar L.P.Kkr Biosimil...,
  
• Eli & Co Lilly Ventures Fun...,
  
• Sankyo Company, Ltd Daiichi,
  
• Georgia Erbez,
  
• Alan C Mendelson,
  Director
• Lee Nisley Newcomer,
  
• Mark Stolper,
  
• Charles W. Newton,
  
• Jill O'donnell Tormey,
  
• Michael Lee Ryan,
  
• Paul Reider,
  Chief Commercial Officer
• Mc David Stilwell,
  Chief Financial Officer
• Bryan J Mc Michael,
  Chief Financial Officer